🇺🇸 FDA
Patent

US 8569337

Tri-cyclic pyrazolopyridine kinase inhibitors

granted A61KA61K31/496A61K31/506

Quick answer

US patent 8569337 (Tri-cyclic pyrazolopyridine kinase inhibitors) held by Vertex Pharmaceuticals Incorporated expires Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Oct 29 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
43
CPC classes
A61K, A61K31/496, A61K31/506, A61P, A61P1/00